© 2005 European Society for Medical Oncology
Original article |
Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in uterine endometrial cancers
Department of Obstetrics and Gynecology, Gifu University School of Medicine, 1-1 Yanagido, Gifu City 501-1194, Japan
* Correspondence to: Dr J. Fujimoto, Department of Obstetrics and Gynecology, Gifu University School of Medicine, 1-1 Yanagido, Gifu City 501-1194, Japan. Tel: +81-58-230-6349; Fax: +81-58-230-6348; Email: jf{at}cc.gifu-u.ac.jp
Background: Angiogenesis is essential for development, growth and advancement of solid tumors. Cyclooxygenase (cox)-2 is recognized as an angiogenic factor in various tumors. This prompted us to study the clinical implications of cox-2 expression and angiogenesis in uterine endometrial cancers.
Patients and methods: Fifty patients underwent curative resection for uterine endometrial cancers. In uterine endometrial cancers, cox-2 levels were determined by enzyme immunoassay, and the localization and counts of microvessels were determined by immunohistochemistry.
Results: There was a significant correlation between microvessel counts and cox-2 levels in uterine endometrial cancers. Cox-2 localized in the cancer cells, but not in the stromal cells of uterine endometrial cancer tissues. Cox-2 levels decreased with the advancement. Furthermore, cox-2 levels significantly correlated with VEGF levels in uterine endometrial cancers.
Conclusions: VEGF associated with cox-2 might work on angiogenesis at an early status in growth. Therefore, long-term administration of cox-2 inhibitors might be effective in the suppression of recurrent initiation of uterine endometrial cancers after curative resection.
Key words: angiogenesis, cox-2, uterine endometrial cancer, VEGF
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Sahin, E. Sahin, and S. Gumuslu Cyclooxygenase-2 in Cancer and Angiogenesis Angiology, April 1, 2009; 60(2): 242 - 253. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Daikoku, Y. Hirota, S. Tranguch, A. R. Joshi, F. J. DeMayo, J. P. Lydon, L. H. Ellenson, and S. K. Dey Conditional Loss of Uterine Pten Unfailingly and Rapidly Induces Endometrial Cancer in Mice Cancer Res., July 15, 2008; 68(14): 5619 - 5627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Altundag, O. Altundag, P. Morandi, and B. Ozcakar Cyclooxygenase inhibitors may be more effective in hormone-dependent endometrial cancers: interaction between cyclooxygenase and aromatase Ann. Onc., September 1, 2005; 16(9): 1559 - 1559. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ghielmini Multimodality Therapies and Optimal Schedule of Antibodies: Rituximab in Lymphoma as an Example Hematology, January 1, 2005; 2005(1): 321 - 328. [Abstract] [Full Text] [PDF]
|
|